Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate [ORR], proportion of patients with complete response [CR] plus partial response [PR]) until 18 weeks of first-line treatment with BI 695502 plus chemotherapy versus Avastin® plus chemotherapy followed by maintenance monotherapy with either BI 695502 or Avastin®.
Critère d'inclusion
- Carcinoma, Non-Small-Cell Lung